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Abstract
Liqui-pellet is a new dosage form stemming from pelletisation technology and concept from liquisolid technology. In spite of liqui-
pellet overcoming a major hurdle in liquisolid technology through achieving excellent flow property with high liquid load factor, the
formulation requires to be optimised in order to improve drug release rate. Liqui-pellets of naproxen containing Tween 80, Primojel,
Avicel and Aerosil were extruded and spheronised. Flowability test confirmed that all liqui-pellet formulations have excellent-good
flow property (Carr’s index between 3.9–11.17%), including liqui-pellets with a high liquid load factor of 1.52, where 38% of the total
mass is co-solvent. This shows a relatively high liquid load factor can be achieved in liqui-pellet without compromising the flowability,
which is one of the key novelty of this work. It was found that the improved drug release rate was due to the remarkably improved
disintegration of the supposedly non-disintegrating microcrystalline-based pellet; the optimised liqui-pellet seems to explode into
fragments in the dissolution medium. At pH 1.2, the optimised formulation had ~ 10% more drug release than non-optimised
formulation after 2 h, and at pH 7.4, the drug release of the optimised pellet was nearing 100% at ~ 15 min, whereas the none-
optimised pellet only achieved ~ 79% drug release after 2 h. DSC and XRPD indicated an increase in the dissolution rate could be due
to molecularly dispersion of naproxen in the pellets. Overall results showed that liqui-pellet exhibited an enhanced drug release and the
capacity for high liquid load factor whilst maintaining excellent flowability, rendering it a potentially commercially feasible drug
delivery system.
Keywords Liquisolid . Liquisolid pellet . Liqui-pellet . Dissolution enhancement . Extrusion-spheronisation . Liquid vehicle .
Solid-state analysis
Introduction
Liqui-pellet is considered the novel emerging oral dosage form. It
stems from liquisolid technology; however, liqui-pellet comes
under liqui-mass system, which is different from liquisolid sys-
tem. This liqui-mass system is combined with pelletisation tech-
nology, producing liqui-pellet [1]. In recent years, the advance-
ment on the high-throughput screening has indicated an in-
creased number of drug candidates to be either poorly water
soluble or insoluble [2]. Since water-insoluble drugs have poor
dissolution rate, the pharmaceutical industry has been challenged
to overcome this in order to improve bioavailability [3]. In fact,
approximately 40% of drugs in the market are considered poorly
soluble in gastrointestinal fluids, and around 90% of drugs in
development are identified as poorly soluble; both of which is
based on biopharmaceutical classification system (BCS) [4].
Liqui-mass system (Fig. 1) is similar to liquisolid system in
that it comprises a solubilised active pharmaceutical ingredient
(API) in an appropriate co-solvent, which form the liquid medi-
cation. This liquid medication is absorbed and adsorbed into a
carrier, which is usually microcrystalline cellulose. The admix-
ture is then coated with a coating material that is usually
nanosized silicon dioxide [3, 5]. Other excipients, namely
superdisintegrant, are usually added to improve dissolution rate.
The major difference in liqui-mass system and liquisolid system
is that the admixture of API and excipients is not necessarily a
free-flowing powder in liqui-mass system, but instead can be a
wet mass/paste. This is different from liquisolid system in which
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it is made clear that the admixture as a free-flowing powder. It
should be noted that liqui-pellet is different from liquisolid pellet
in that liqui-pellet is under liqui-mass system. The name liqui-
pellet also aid the distinction from liquisolid pellet in that liqui-
pellet is capable of high liquid load factor.
It is noteworthy to point out that the technology involving
liqui-mass system is highly versatile. It can be seen in Fig. 1
that liqui-mass system encompasses wet mass/paste and but
less frequently free-flowing powder. In concept, the technol-
ogy concerning liqui-mass system can produce free granule,
moldable sheets, liqui-pellet, liqui-tablet and more, which will
be revealed in future studies. There is also a considerable
flexibility for modifications of the formulation, particularly
the coating of liqui-pellet. Such versatility makes this new
liqui-mass system interesting and exciting to explore. In addi-
tion, this technology has major advantages such as being cost-
effective, mainly uses green technology, simplistic approach,
easy to scale up platform technology for commercial
manufacturing, does not require organic volatile solvent, no
need for an advance technique or machinery and excipient are
common and easily obtainable [6]. Such advantages may not
be present in other various technologies confronting the same
issue of improving the bioavailability of poorly water-soluble
drugs. Other technologies include conversion of crystalline
drug into its amorphous state [7], solid dispersion [8];
micronisation [9–12], nanosuspension [13, 14], co-grinding
[15–17], self-emulsifying drug delivery system [18, 19] and
inclusion of drug solution in soft gelatin capsule [20]. It is
claimed that the liqui-pellet is highly commercially feasible
and has the potential to play a major role in the future oral
dosage form [1].
The key purpose of liqui-pellet is to take the key advan-
tages of liquisolid formulation into a commercially feasible
dosage form. This is done by confronting the major draw-
backs in liquisolid technology, such as poor flow property,
poor compactibility and inability to produce high-dose drug
without being too bulky and heavy for real-life use [3, 5]. In
the authors’ previous studies, it is shown that liqui-pellet can
achieve excellent flow property whilst having a high liquid
load factor of [1]. Liqui-pellet not only contains the advan-
tages of liquisolid technology, but it also has the inherent
advantages of being in a pellet form. Such advantages include
good flow property [21], potential to combine incompatible
drugs or drugs with different release profiles in same dose unit
[22], reduced risk of side effects due to dose dumping and the
flexibility for modification via coating technology.
The aim of the present study is to optimise liqui-pellet
formulation in order to improve the drug release rate of
naproxen, which is a nonsteroidal anti-inflammatory drug
(NSAID), belonging to BSC class II. The chosen liquid vehi-
cle used in the investigation is Tween 80, as it was considered
the most suitable liquid vehicle from previous studies [1].
Tween 80 solubilises the API as well as acting as a surface-
active agent which reduces interfacial tension and improve
water penetrating into the dosage form.
Materials and methods
Materials
Naproxen was obtained from Tokyo Chemical Industry Co
(Japan). Other excipients used to prepare the liqui-pellet in-
cluded microcrystalline cellulose (Avicel PH-101), (FMC
corp., UK), hydrophilic fumed silica with specific surface area
of 300 m2/g (Aerosil 300) (Evonik Industries AG, Hanau,
Germany), sodium starch glycolate Type A (Primojel) (DFE
Pharma, Goch, Germany), croscarmellose (Primellose) (DFE
Pharma., Goch, Germany), 2-propanol (VWR Chemicals,
Fontenay Sous Bois France), polysorbate 80 (Tween 80) and
PEG with molecular weight of 1500 (Acros Organics, UK).
All other reagents and solvent were of analytical grades.
Preparation of naproxen liqui-pellet
The pestle and mortar method was applied to mix naproxen in
Tween 80 to form the liquid medication. Avicel PH-101
(carrier) and Aerosil 300 (coating materials) were used in all
the formulation with a ratio of carrier to coating material of 20.
The liquid medication was then incorporated into Avicel be-
fore transferring into a mixer (Caleva Multitab, Caleva
Process Solutions Ltd., UK), where the sample was mixed
for 10 min at a constant rate of 125 rpm with deionised water
added bit by bit to achieve reasonable plastic property for
Fig. 1 Diagram summarising the novel liqui-mass system which is used to make liqui-pellet
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extrusion (Caleva Multitab, Caleva Process Solutions Ltd.,
UK). Aerosil 300 was then added into the admixture and fur-
ther mixed for 10 min before extrusion. Once the sample was
extruded, the extrudate was spheronised at an almost constant
rotation at 4000 rpm (decrease to 3500 rpm if agglomeration
seemed likely or increase to 4500 rpm to increase pellet sphe-
ricity). The spheronisation time varied depending on the
extrudate plastic property to avoid agglomeration. Pellets
were then placed in an oven under a constant temperature of
50 °C overnight to remove water content.
For clarity, it should be mentioned that the liqui-pellet for-
mulations were categorised into two sections (Table 1). In the
first section between LP-1 to LP-6, the main focus was to look
into the effect of varying concentration of a Primojel
(superdisintegrant) with and without the presence of Tween
80. In the second section of the formulations between LP-7
and LP-11, the focus was to modify the formulations in an
attempt to improve drug release rate.
Evaluation of naproxen liqui-pellet
Flowability test on liqui-pellet
Three techniques were used to evaluate the flow properties of
the liqui-pellet formulations, namely flow rate in grams per
second (Flowability tester, Copley Scientific, UK), angle of
repose (Flowability tester, Copley Scientific, UK and
Digimatic height gauge, Mitutoyo, Japan) and Carr’s com-
pressibility index using the SVM tapped density tester
(D-63150, Erweka, Germany). Flow rates were measured by
recording the weight (g) and time (s) of pellets flowing
through a 10-mm-diameter orifice after applying the shutter.
Note that shutter was applied before the funnel holding the
pellet became empty. To determine the angle of repose, the
pellets were placed in a funnel with 10-mm-diameter orifice
and let the pellets flow onto a 100-mm-diameter circular test
platform. The digimatic height gauge and micrometre were
used to measure the height and diameter of the heap of the
sample, so that the angle of repose could be determined. Carr’s
compressibility index (CI%) was calculated using CI equa-
tion. Tapped density was measured using the tapped density
tester, which was set to tap 100 times. All measurements were
done in triplicates.
Friability test on of liqui-pellet
The friability test was adapted using a similar method as in Hu
studies [23]. Two best-optimised formulations were tested.
Pellets (3 g) and glass beads (3 g) were placed in Erweka
friabilator (D-63150, Erweka, Germany) and sealed to prevent
pellets from leaving the container. The friabilator was then
rotated under the constant speed of 25 rpm for 4 min.
Weight of the pellets before and after the friability test was
recorded and used to calculate the percentage of weight loss.
Particle size analysis via sieve method
The particle size distribution was determined using sieve
method (Test sieve, Retsch, Germany). Only the physical mix-
ture pellet and two chosen optimised formulations were tested.
Pellets (5 g) were sieved under vibration using the mechanical
shaker (AS 200, Retsch, Germany) for 1 min with an ampli-
tude of 50, then a further 9 min with an amplitude of 40. The
size of sieves used were 2000-, 1000-, 850-, 500- and 250-μm
sieves. The pellets yield was determined based on the pellet
fraction between 250 and 2000 μm and presented as the per-
centage of total pellet weight.
Stereoscopic analysis
Mean Feret’s diameter along with mean roundness and mean
elongation ratio was determined using an optical microscope
(Nikon Labophot, Nikon, Japan) connected to a camera
(Panasonic camera WVCL310, Panasonic, Japan). The image
of a pellet was captured and processed using particle size
analysis software V1999 (designed in-house at King’s
College London). This was repeated so that 100 pellets were
analysed per formulation in order to obtain Feret’s diameter
and also shape factors such as roundness and elongation ratio.
Roundness and elongation ratio were calculated using Eqs. 1
and 2 respectively [24]. Only physical mixture pellet and two
best-optimised formulations underwent stereoscopic analysis.
Roundness ¼ perimeterð Þ2= 4πAð Þ ð1Þ
Elongation ratio ¼ Maximum Feret diameter=Minimum Feret diameter
ð2Þ
Scanning electron microscope analysis
Surface morphology studies of the liqui-pellet from each for-
mulation were carried out using a scanning electron micro-
scope (Jeol JMS 820, Freising, Germany). The samples were
placed on a double-sided carbon tape and sputter-coated with
gold using a sputter coater (Edwards S-150 sputter coater,
Edwards High Vacuum Co. International, USA) with gold
target and Argon gas under 5 kV for 5 min. After the samples
were coated, it was ready to be placed into the scanning elec-
tron microscope (SEM) where surface structure was then ob-
served and recorded at magnifications of × 80, × 200 and ×
800, using the SEM which was operating at 3 kV.
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In vitro drug dissolution test
The USP dissolution paddle method (708-DS Dissolution
Apparatus & Cary 60 UV-Vis, Agilent Technologies, USA)
was carried out for all formulations. All dissolution tests of the
pellets in capsule were under the constant condition of 900 ml
dissolution medium, paddle rotating at 50 rpm and tempera-
ture of 37.3 ± 0.5 °C.
Dissolution media that were used were either HCl buffer
solution of pH 1.2 or phosphate buffer solution of pH 7.4 to
simulate gastric fluid or intestinal fluid respectively without
enzymes. The absorbance of the samples was taken at time
intervals of 5 min for 1 h, and then time interval of 10 min for
another hour. The authors were aware that at pH 1.2, the sink
condition was not maintained; however, this pHwas only used
for comparison of various formulations.
All formulations contained 25 mg of naproxen and this
amount of naproxen was chosen due to its poor solubility
profile at pH 1.2. This weakly acidic drug would need to be
able to dissolve completely at pH 1.2 in order for the dissolu-
tion test to be considered reliable. This value was also taken on
the basis of its solubility at 35 °C and pH 1.2 which was
27 mg/l [25]. Although it does not follow the sink conditions,
it can be used for comparison purpose for dissolution profiles
of different formulations. Thus, 25 mg of naproxen seemed
reasonable in this test. At pH 7.4, naproxen was extremely
soluble with a solubility of ~ 3347 mg/l; hence, using 25 mg
of the drug was not a problem.
Solid-state analysis
Differential scanning calorimetry studies
Differential scanning calorimetry (DSC) (DCS 4000, Perkin
Elmer, USA) was performed on the chosen liqui-pellet formu-
lations with the fastest dissolution rate, including its excipients
and pure naproxen in order to indirectly assess the solid state
of naproxen in the formulations using data from thermograms.
Samples weighing between 3 and 6 mg were sealed in alu-
minium pan and placed in the DSC machine with a scanning
rate of 10 °C/min (from 25 to 200 °C) under nitrogen
atmosphere.
X-ray powder diffraction studies
X-ray powder diffraction (XRPD) was performed using X-ray
diffractometer (D5000, Siemens, Germany) on naproxen, ex-
cipients and selected optimised formulations in order to char-
acterise the solid state of the materials used. Samples were
scanned over a range of 2θ at voltage of 40 kV and current
of 30 mA, with scanning angle ranged from 5° to 40° and scan
rate of 0.2°/s.
The percent relative crystallinity was calculated using inte-
grated peak method (Eq. 3) and peak height method (Eq. 4)
[26]. Trapezoid method was applied to calculate the area un-
der the curve for integrated peak method.
%XRD relative crystallinity ¼ As=Arð Þ  100 ð3Þ
%XRD relative crystallinity ¼ H s=H rð Þ  100 ð4Þ
Statistical and mathematical analysis
Mean cumulative % drug release after 2 h from the dissolution
test was statistically analysed by one-way analysis of variance
(ANOVA). Results were quoted as significant where p < 0.05.
Difference factor (f1), Eq. 5, and similarity factor (f2), Eq. 6
[27] were used to determine the differences/similarities in
terms of dissolution profile among the formulations. Such
methods have been recommended by the US FDA (Food
and drug administration) [28] and implemented by the FDA
in various guidance documents [29, 30]. When f1 value is
between 0 and 15 and f2 value is between 50 and 100, this
indicates equivalence of the two dissolution profiles [31].
Details of the equations can be found in various literature
[28, 32–34]. In brief, n represents the number of dissolution
sample times and Rt and Tt represent the mean % of drug
dissolved at each time point (t).
f 1 ¼ ∑t¼1n jRt−Ttj½ = ∑t¼1nRt½ f g  100 ð5Þ
f 2 ¼ 50  log 1þ 1=nð Þ∑t¼1n Rt−Ttð Þ2
h i−0:5
 100
 
ð6Þ
Results and discussion
Evaluation of naproxen liqui-pellet
Liqui-pellet flow property
Results from the flowability tests are shown in Table 2. It is
clear that all formulations have excellent or in the borderline
between excellent to good flow property. Thus, it is claimed
that liqui-pellet is a promising dosage form, which resolves
poor flowability issue in liquisolid technology and yet main-
tains the inherent advantages stemming from liquisolid con-
cept. Pezzini et al. have applied liquisolid system to pellet, but
in the current study, liqui-mass system was used instead [35].
Both liqui-pellet and liquisolid pellet do indeed contain inher-
ent advantage from liquisolid and pelletisation technologies.
However, they are distinctively different in that they both use
different systems (i.e. liqui-mass system versus liquisolid sys-
tem). The potential of Liqui-pellet is that liquid load factor is
Drug Deliv. and Transl. Res.
considerably higher than what liquisolid pellet can ever
achieve.
The previous studies by the authors demonstrated that
liqui-pellets achieved a high liquid load factor of 1, whilst
maintaining excellent flow property [1]. In fact, before the
development of liqui-pellet, it has been proven very difficult
to achieve such mentioned results, due to the cohesive nature
of liquid powder admixture, which is shown in various studies
[36–38]. Tiong et al. formulated naproxen liquisolid powder
with Lf of 0.9 but the flowability was poor (Carr’s index of
31.58) [36]. In studies by Javadzadeh et al., an additive such
as PEG 3500 was used to increase the Lf [37]. They observed
an increase of carbamazepine Lf from 0.25 to 0.6 [37]; how-
ever, it is clear that liqui-pellet Lf is much more superior and
does not need polymeric additive. Hentzschel et al. replaced a
commonly used carrier (Avicel) and coating material (Aerosil)
with neusilin, a material with a much larger specific surface
area (SSA) [38]. This enabled an increase of Lf by a factor of
~ 7; nonetheless, it is still limited by its flow property; their
formulations’ flow rate are below 1 g/s [38].
What is exciting and promising in liqui-pellet is that it can
be further optimised so that the Lf is further increased. It can be
seen in Table 1 that LP-8 has Lf as high as 1.52, where 38% of
the pellet total mass is co-solvent, and yet excellent-good flow
property is achieved. Such a result further supports the
potential of liqui-pellet being commercially feasible. This
means flow property and Lf are not a major hindrance for
liqui-pellets; this emerging novel oral dosage form has the
potential for smooth and cost-effective manufacturing, as well
as producing high-dose liqui-pellet without being overly
bulky and heavy if the formulation is optimised. Although
Pezzini et al. [35] overcome the flow issue of liquisolid by
converting it to pellet form, the load factor calculated was
around 0.1 (they did not calculate the load factor and the
authors of the current research calculated it on the basis of
mass data provided in Pezzini’s article), which is much lower
than the load factor obtained in the current article (Lf ≥ 1). This
indicates that at the same concentration of API, the final for-
mulation in Pezzini’s article should be very bulky. In addition
to load factor, the percentage of API in Pezzini formulation
was around 5% (percentage of API was calculated on the basis
of mass data provided in Pezzini’s article). This is lower than
the majority of liqui-pellet formulation, which is around 19%
(percentage of API was calculated on the basis of mass data in
Table 1).
Friability test
Table 3 shows the results obtained from the friability test of
the physical mixture pellet and two optimised formulations
(LP-8 and LP-11). In brief, they all have percentage weight
loss below 1%. Since there is currently no standard for fria-
bility test on pellets, USP standard friability test for tablet is
adapted, which suggests less than 1% weight loss is accept-
able. Therefore, it can be concluded that all tested formula-
tions are robust, which is ideal for commercial manufacturing
in terms of quality control.
Table 3 Weight loss of
3 g of each formulation
under rotational speed of
25 rpm for 4 min
Formulation % weight loss
Physical mixture pellet 0.54
LP-8 0.03
LP-11 0.12
Table 2 Flow rate (g/s), angle of repose and Carr’s compressible index (CI%) of all liqui-pellet formulation (n = 3)
Formulationa Flow rate
(g/s) ± SDb
Angle of repose ± SDb CI% ± SDb Inference according to angle of repose Inference according to CI%
Physical mixture pellet 8.02 ± 0.24 27.95 ± 0.14 9.08 ± 0.87 Excellent flow property Excellent flow property
LP-1 7.60 ± 0.10 26.98 ± 0.74 5.25 ± 0.86 Excellent flow property Excellent flow property
LP-2 7.61 ± 0.12 27.75 ± 0.31 8.13 ± 1.65 Excellent flow property Excellent flow property
LP-3 7.42 ± 0.22 28.68 ± 0.53 6.07 ± 1.44 Excellent flow property Excellent flow property
LP-4 10.68 ± 0.06 23.81 ± 0.40 9.95 ± 0.08 Excellent flow property Excellent flow property
LP-5 8.59 ± 0.08 28.20 ± 0.16 11.17 ± 0.85 Excellent flow property Good flow property
LP-6 6.96 ± 0.28 29.21 ± 0.26 10.37 ± 0.79 Excellent flow property Excellent-good flow property
LP-7 7.13 ± 0.07 28.68 ± 0.22 7.24 ± 2.33 Excellent flow property Excellent flow property
LP-8 5.82 ± 0.09 30.51 ± 0.38 3.90 ± 2.30 Excellent-good flow property Excellent flow property
LP-9 7.35 ± 0.05 28.57 ± 0.50 7.63 ± 1.42 Excellent flow property Excellent flow property
LP-10 6.47 ± 0.19 30.13 ± 0.19 9.24 ± 0.73 Excellent-good flow property Excellent flow property
LP-11 6.03 ± 0.25 30.47 ± 0.51 7.76 ± 0.76 Excellent-good flow property Excellent flow property
a For the composition of each formula refer to Table 1
b SD, standard deviation from the mean
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It can also be postulated that the robustness is due to micro-
crystalline cellulose (carrier) forming sufficient bonds within its
structure when water is added, hence producing robust pellets.
In addition, the Tween 80 in the liqui-pellet can increase the
pellet plasticity due to plasticising effect [39], which effectively
increases the pellet resistant to friability.
Fig. 2 Particle size distribution of LP-8 (top), LP-11 (middle) and physical mixture pellet (bottom)
Table 4 Stereoscopic analysis
showing the mean Feret’s
diameter, mean roundness and
mean elongation of physical
mixture pellet and optimised
formulation (n = 100)
Formulationsa Mean Feret’s diameter
(mm)
Mean roundness ±
SDb
Mean elongation ratio ±
SDb
Physical mixture pellet 1.028 1.25 ± 0.12 1.41 ± 0.19
LP-8 1.431 1.28 ± 0.14 1.43 ± 0.21
LP-11 1.527 1.42 ± 0.12 1.95 ± 0.35
a For the composition of each formula, refer to Table 1
b SD, standard deviation from the mean
Drug Deliv. and Transl. Res.
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Particle size analysis via sieve method
Results from particle size analysis of the optimised formu-
lation LP-8 (Fig. 2) indicate that ~ 97% of the pellets fall in
the size of 1 mm. This shows that the optimised liqui-pellet
LP-8, have a good uniformity of size. This is ideal in per-
spective of manufacturing. There will be less likelihood of
variation in volume of pellet during encapsulation, conse-
quently maintaining uniformity of drug content during fill-
ing process.
Particle size analysis of LP-11 shows a wider size distribu-
tionwith ~ 64% fall in the size of 850μm and ~ 32% fall in the
size of 1 mm. This could be due to the reduced plastic property
as a result of a reduction in water content, leading to a poorer
quality pellet with wider size distribution.
Nonetheless, both of the optimised formulations are almost
entirely below 2-mm range which will behave similarly to
liquid in the stomach and be emptied into the small intestine
relatively fast [40]. This can be beneficial for weakly acidic
drugs (i.e. naproxen), as they are more soluble in an alkaline
environment, suggesting that bioavailability and onset of ac-
tion may be improved.
It is also interesting to note that most of the physical mix-
ture pellet falls in 500 μm, which is considered small. This
supports the claim from the previous studies by the authors
that co-solvent tends to increased pellet size [41].
Stereoscopic analysis
The Feret’s diameter (Table 4) agrees with the trend that co-
solvent tends to increase liqui-pellet size. It can be seen that
physical mixture and LP-11 mean Ferret diameter
overestimated the liqui-pellet size. Since the pellets are not
perfectly spherical, they tend to be in their most stable orien-
tation. This means that the smallest dimension is orientated
vertically; therefore, overestimation is prone to occur [42].
It is clear that LP-11 is the least round with mean roundness
deviating from 1 considerably (1.42). Its mean elongation ra-
tio is also large which supports the visible observation of the
cylindrical liqui-pellet. Perhaps the reduced plastic property
due to decreased water content leads to incomplete spheres
forming. Nonetheless, LP-11 has excellent-good flowability.
Scanning electron microscope analysis
The SEM results (Fig. 3) show physical mixture pellet (PMP)
has the roughest surface structure compared to the rest of the
formulations. This can be seen clearly at × 800 magnification.
Although formulation LP-1, which contains 28% Tween 80,
shows surface crack at × 80 magnification, its surface is less
rough than the physical mixture pellet. This is more apparent
Fig. 4 Dissolution profile of pellets in capsule for naproxen 25 mg with different concentrations of Primojel (5, 10 and 15% w/w) with and without
Tween 80 (pH 1.2)
Fig. 3 Images from SEM of physical mixture pellet, LP-7, LP-8 and LP-
11; (I) × 80 magnification, (II) × 200 magnification and (III) × 800
magnification
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at × 200 and × 800 magnification. The formulation LP-8,
which contains 38% Tween 80, shows a remarkable reduction
in surface roughness compared to LP-1. This indicates that
surface structure becomes less rough as Tween 80 is increased.
The observation supports the claimmade from the previous
studies by the authors that co-solvent influences surface struc-
ture, which tends to make the surface smoother [1]. It is spec-
ulated from the previous studies that liquid vehicle may re-
duce the crystallinity of the pellet, resulting in smoother sur-
face structure.
The SEM image of formulation LP-11 shows a large num-
ber of cracks in the pellet compared to LP-8. In LP-11, which
also contains Tween 80 as liquid vehicle, the water content is
reduced during the manufacturing of the liqui-pellet. Water
and 2-propanol mixture is used instead of just water to reduce
overall water content during production. With a reduced
amount of water, there will be less bonding within the MCC
structure; thus, the pellet quality is reduced. Nonetheless, this
is advantageous as the pellet was able to disintegrate well in
dissolution medium.
In formulation LP-10, PEG (molecular weight of 1500) and
water mixture is used tomake the liqui-pellet. It is thought that
the PEG at the surface of the pellets will dissolve faster,
forming pores. However, it is clear in Fig. 3 image LP-10b,
there is no apparent porous structure but the surface did be-
come rougher.
Drug release study
Asmentioned in the previous studies by the authors, naproxen
has poor solubility in acidic condition; however, for compar-
ison purpose, the dissolution of liqui-pellets was carried out at
pH 1.2. The authors have found that Tween 80 appears to be
the most suitable co-solvent for naproxen liqui-pellet [41];
hence, Tween 80 is the chosen liquid vehicle in this study.
As observed in the previous dissolution study of liqui-pellet,
Fig. 5 Dissolution profile of pellets in capsule for naproxen 25 mg with various modifications in attempt to improve dissolution rate (pH 1.2)
Fig. 6 An image of LP-8 liqui-pellet disintegrate explosively in acidic
dissolution medium. Note the small white specks are fragments of the
liqui-pellet
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the lack of disintegrating properties of Avicel led to poor drug
dissolution rate [1]. In an attempt to promote disintegration, a
superdisintegrant (Primojel) with different concentrations (5,
10, 15% w/w) is introduced into the formulation.
Dissolution test of the formulations containing 5%, 10%
and 15% w/w of Primojel with and without liquid vehicle is
shown in Fig. 4. Liqui-pellet formulations containing 5 and
10% w/w Primojel (LP-1 and LP-2 respectively) had similar
dissolution profiles (F1 = 3.3 and F2 = 97.84). It can be seen
that increasing Primojel concentration to 15% w/w (LP-3)
slightly impedes dissolution by ~ 5% in comparison to formu-
lations containing 5% w/w (LP-1) and 10% w/w (LP-2)
Primojel. When comparing LP-1 (Primogel 5% w/w) and
LP-3 (Primogel 15% w/w), F1 = 18.91 and F2 = 80.81. It can
be seen the F1 value mentioned is above 15, indicating differ-
ences in the drug release profile due; however, the F2 value
suggests equivalence. If F1 is favoured over F2 and assuming
15% Primojel is slowing down drug release compared to 5%
Primojel, this may be due to Primojel forming gel, which can
slow down drug release rate. Literature claims that the re-
quired concentration of Primojel to achieve optimum disinte-
gration action is ~ 4% w/w [43]. Given this claim, Primojel
with concentration of 5%w/w is chosen as opposed to 10% for
the other formulations. Results from Fig. 4 confirm formula-
tion without a liquid vehicle has considerably slower drug
release rate compared to the one with liquid vehicle
(p < 0.05). In fact, even with different concentration of
Primojel incorporated into the formulation (LP-4, LP-5 and
LP-6), the dissolution profiles are similar to that of physical
mixture pellet (p > 0.05). This further confirms that the char-
acteristic of enhanced drug release in liquisolid formulations
can be maintained in liqui-pellet.
After the most suitable liquid vehicle and concentration of
Primojel are chosen, various modifications are applied to the
formulation to further improve the drug release rate. As seen
in Fig. 5, a formulation containing an increased Tween 80 and
decreased carrier and coating materials (LP-8) shows the best
enhanced drug release profile.
When comparing LP-8 to the non-optimised naproxen
liqui-pellet containing Tween 80 (LP-1), it can be seen that
the drug release from LP-8 is ~ 10% higher (p < 0.05) and
~ 25% higher than physical mixture pellet (p < 0.05) after
2 h. This shows the potential of increasing drug dissolution
rate of liqui-pellet when the formulation is optimised. In addi-
tion to LP-8 having the fastest drug release rate, its liquid load
factor is higher than other formulations (Lf = 1.52), whilst still
maintaining excellent-good flow property. With the increase in
Tween 80, less water is required to achieve the appropriate
level of plasticity of the extrudate for making quality pellets
when spheronised. This is due to the Tween 80 plasticising
effect [39]. With less water included in the formulation, it
can be deduced that the amount of bonding within the micro-
crystalline cellulose structure is reduced. Thus, disintegration
is more rapid, which is visibly observable during dissolution
test (Fig. 6). In fact, the disintegration is rather fast and explo-
sive, which is the reason for higher drug release rate. One of the
limitations of microcrystalline cellulose carrier in pelletisation
via extrusion-spheronisation is the difficulty of achieving en-
hanced drug release due to strong bonding, rendering the pellet
none disintegrating [44]. In spite of this, microcrystalline cel-
lulose is used because it is the gold standard in extrusion and
spheronisation technology as it has the proper rheological
properties, cohesiveness and plasticity to yield strong spherical
pellets [45]. Formulation LP-11 has the second best enhanced
drug release rate (~ 26%within 2 h). This can be explained in a
similar manner to LP-8, where 2-propanol andwater mixture is
used during the liqui-pellet preparation, which effectively re-
duces the amount of water. Hence, bonding force within mi-
crocrystalline cellulose is reduced, leading to improvement in
the propensity for disintegration.
It is found that the stage at which Primojel is added
during formulation has a slight effect on how well the
superdisintegrant performs. When Primojel is added into
the liqui-mass system after coating material (LP-7), the
drug release rate is ~ 5% lower than the same formulation
where Primojel is added in the early stage along with the
carrier (LP-1). The F1 = 27.81 and F2 = 74.83. F1 indicates
a difference in their dissolution profile but F2 indicates
equivalence. It should be noted that the range of F1 and
F2 indicating difference or equivalence is only a sugges-
tion from FDA [32] and the basis of the criteria for de-
termining the difference and similarity between dissolution
profiles are unclear. In fact, F2 is insensitive to the shape
of the dissolution profile and is a sample statistic that
cannot be used in formulating a statistical hypothesis for
the assessment of dissolution similarity [32, 34]. This
makes it impossible to evaluate false positive or false
negative. With the assumption that F1 is reliable, the
stages of when Primojel is added does have an influence
on drug release rate. I t can be seen that the
superdisintegrant is added extragranularly in LP-7 and
intragranularly in LP-1. Intragranular incorporation of
Primojel appears to be more effective than extragranular
for improving drug release. This reflects the importance of
having an optimum procedure for preparing liqui-pellet. In
literature, a combination of intragranular and extragranular
incorporation of superdisintegrant is most effective in pro-
moting disintegration [46–48].
In formulation LP-9, Primojel superdisintegrant is replaced
by Primellose to see if the sodium starch glycolate or
croscarmellose sodium (respectively) will perform better.
Results from Fig. 6 shows Primojel (LP-1) have ~ 4% more
drug release than Primellose (LP-9) after 2 h (F1 = 36.94 and
F2 = 71.10). If F1 is taken into account, then this suggests
Primojel is the better superdisintegrant of choice for naproxen
liqui-pellet.
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In formulation LP-10, PEG (molecular weight of 1500) and
water mixture was used to make the liqui-pellet. It is thought
that the PEG at the surface of the pellets will dissolve faster,
forming pores which can facilitate the penetration of water
into pellets; or that the liquid medication can move out easily
via the pores generated as a result of the dissolution of PEG in
dissolution medium. However, the results show similar drug
release rate to that of LP-7; thus, no improvement in
dissolution rate is observed. The SEM results (Fig. 3) show
that LP-10 surface is rougher after the dissolution test, but the
porous structure is not apparent. Without the porous structure,
the drug release rate would not improve.
USP pharmacopoeia suggests performing the dissolu-
tion test at pH 7.4 to maintain sink conditions. On the
basis of this, the authors believe that those formulations
which show higher dissolution at pH 1.2 should exhibit
Fig. 7 Dissolution profile of formulations containing naproxen 25mg with the fastest dissolution rate after modifications, formulation containing Tween
80 as liquid vehicle with Primojel 5% w/w, and physical mixture pellets (pH 7.4)
Fig. 8 DSC thermogram of naproxen
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the better dissolution at higher pH; therefore, only the
optimised formulation (LP-8 and LP-11) is selected for
dissolution test at pH 7.4 (Fig. 7). The results show both
formulations are reaching near plateau after 20 min
(~ 100% drug release within 20 min). This fast dissolution
profile is to be expected, as naproxen is a weakly acidic
drug; hence, it will dissolve more rapidly in a basic envi-
ronment. In brief, the results show naproxen liqui-pellet is
capable of achieving a fast release rate even though there
have been claims that microcrystalline cellulose-based
pellets prepared via extrusion-spheronisation tend to pro-
long drug release [49]. In addition, since the pellets are
small, i.e. ~ 98.8% of both LP-8 and LP-11 fall into the
size of 1 mm or below; these pellets will undergo gastric
emptying relatively fast, similar to liquid [40]. It will be
exposed to basic environment relatively quick; thus, drug
dissolution should occur faster and potentially improve
the drug bioavailability. Also, since the pellets are small,
it will be well distributed along the gastrointestinal tract,
which could further improve bioavailability [40].
According to results shown in Fig. 6, it seems that water
content during the preparation of the liqui-pellet plays a major
role in disintegration and drug release rate. It is clear that
reducing the water content causes a significant improvement
in drug release, most likely due to reduced bonding force
within the microcrystalline cellulose structure, which im-
proves disintegration. Furthermore, Avicel has disintegrant
properties [43], which are displayed with reduced water con-
tent formulations. The drug release rate of the reduced water
formulations (LP-8 and LP-11) nearly reached towards the
plateau after 20 min, whereas a formulation without reduced
water content (LP-1) only has ~ 79% drug release after 2 h.
When comparing the results from Figs. 5 and 7 to
Tiong et al. studies [36] on naproxen liquisolid compact,
liquisolid tablets showed faster drug release rate at
pH 1.2; however, at pH 7.4, the dissolution rate for the
optimised formulations are similar or slightly better than
Tiong et al. With excellent-good flow property being
achieved in liqui-pellet and the intrinsic advantages of
liqui-pellet, including possible room for further modifica-
tions, the novel liqui-pellet seems like a promising ap-
proach in tackling bioavailability issue of poorly water-
soluble drugs in a commercially feasible and cost-
effective way.
Fig. 9 DSC thermograms of Avicel, Aerosil, Primojel physical mixture pellet, LP-8 and LP-11. Note the scales of Avicel, Aerosil and Primojel are the
same but different from physical mixture, LP-8 and LP-11
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DSC studies
The DSC traces of naproxen, Avicel, Aerosil, Primojel, phys-
ical mixture pellets and some optimised liqui-pellet formula-
tions are shown in Figs. 8 and 9. The naproxen trace shows a
sharp endothermic peak (Tm = 158.77 °C andΔH = 92.06 J/g)
indicating its crystalline state. Avicel (Tm = 72.67 °C and
ΔH = 94.82 J/g) and Primojel (Tm = 83.82 °C and ΔH =
167.36 J/g) thermograms displayed broad peak. These peaks
could be due to water within Avicel and Primojel evaporating,
as they are hygroscopic materials. Tiong et al. also observed
the evaporation of water from Avicel [36]. As for Aerosil,
there was no definitive peak.
When comparing naproxen and physical mixture pellet
thermograms as shown in Figs. 8 and 9, it can be seen that
there is a small shift of peak from 158.77 to 149.80 °C respec-
tively. This could be due to Avicel influencing the overall peak
of naproxen in the physical mixture pellet. Nonetheless, the
crystalline state of naproxen is still present. However, when
looking at the DSC traces of optimised formulations (liqui-
pellets), LP-8 (Tm = 111.01 °C andΔH = 2.04 J/g) and LP-11
(Tm = 120.69 °C and ΔH = 2.83 J/g), the naproxen peak was
absent and the Tm lowered, indicating that they were less crys-
talline and possibly more amorphous, hence the improvement
in dissolution.
XRPD studies
Figure 10 shows major peaks of naproxen at 2θ values of 12.2,
16.2, 18.4, 19.6, 22.2, 23.2, 26.8 and 27.8° which are also
reported by Maghsoodi et al. [50], with the exception of a
sharp peak at ~ 7° being present and peak at 26.8° being ab-
sent in Maghsoodi studies. Another research carried out by
Mello and Ricci-Junior [51] showed some variation in
naproxen peaks between different studies. This could be due
to different scan rate settings or the actual state or form of the
drug used in various studies. Nonetheless, the general peaks of
naproxen are present.
The XRPD diffractogram of physical mixture pellet and
formulation LP-8 and LP-11 has no peak other than that of
naproxen and Avicel, which indicates no interaction between
the excipients and the drug (Fig. 10). As in LP formulations,
naproxen is in a molecularly dispersed state; therefore, it is
expected to have more halo XRPD compared to the physical
mixtures. Figure 9 does not show a big difference in XRPD
between the physical mixtures and LP formulations. This
could be due to the presence of a high concentration of amor-
phous Avicel which overshadow the overall XRPD peaks in
the physical mixtures. The percentage crystallinity was calcu-
lated on the basis of Eqs. 3 and 4 showed that LP8 had the
lowest crystallinity (18% and 36% using Eqs. 3 and 4
Fig. 10 Diffractograms of naproxen, Avicel, Aerosil, Primojel, physical mixture pellet, LP-8 and LP-11
Drug Deliv. and Transl. Res.
respectively) compared to physical mixtures which are 23%
and 40%. The authors believed that the crystallinity of the
physical mixtures should be much higher than the reported
values in this study which could be due to the presence of a
high concentration of Avicel in the sample as described earlier.
Conclusion
It is confirmed that optimised liqui-pellet is capable of en-
hanced drug release when propensity for disintegration is im-
proved. Although Avicel is known to be non-disintegrating,
when the water content is reduced during liqui-pellet produc-
tion, the pellet is capable of fast and even explosive disinte-
gration. The major drawback of classical liquisolid formula-
tion having poor flowability has been overcome by replacing
it with the new liqui-pellet dosage form. All liqui-pellet for-
mulation maintained excellent-good flow properties evenwith
an extremely high liquid load factor of 1.52, where 38% of
total pellet mass is co-solvent. In conclusion, it is reasonable
to postulate that liqui-pellet is highly commercially feasible
without having the advantages of liquisolid formulation com-
promised. Furthermore, there is potential for further optimisa-
tion of this novel delivery system as the parameters have yet to
be optimised.
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